6/11
02:11 pm
exas
Exact Sciences: Still No Reason To Own [Seeking Alpha]
Low
Report
Exact Sciences: Still No Reason To Own [Seeking Alpha]
6/7
01:21 pm
exas
Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report? [Yahoo! Finance]
6/7
10:51 am
exas
Exact Sciences (NASDAQ:EXAS) shareholders have endured a 63% loss from investing in the stock three years ago [Yahoo! Finance]
Low
Report
Exact Sciences (NASDAQ:EXAS) shareholders have endured a 63% loss from investing in the stock three years ago [Yahoo! Finance]
6/4
07:28 am
exas
UltraSight and Mayo Clinic join forces for AI-driven cardiac care [Yahoo! Finance]
Low
Report
UltraSight and Mayo Clinic join forces for AI-driven cardiac care [Yahoo! Finance]
6/3
04:44 pm
exas
Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential? [Yahoo! Finance]
Medium
Report
Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential? [Yahoo! Finance]
6/3
11:05 am
exas
Exact Sciences Co. (NASDAQ: EXAS) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $75.00 price target on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $75.00 price target on the stock.
5/29
01:09 pm
exas
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition [Yahoo! Finance]
Low
Report
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition [Yahoo! Finance]
5/28
12:34 pm
exas
Exact Sciences (EXAS) to Showcase Favorable Research Outcome [Yahoo! Finance]
Low
Report
Exact Sciences (EXAS) to Showcase Favorable Research Outcome [Yahoo! Finance]
5/28
06:08 am
exas
Exact Sciences to Participate in June Investor Conferences [Yahoo! Finance]
Medium
Report
Exact Sciences to Participate in June Investor Conferences [Yahoo! Finance]
5/28
06:00 am
exas
Exact Sciences to Participate in June Investor Conferences
Medium
Report
Exact Sciences to Participate in June Investor Conferences
5/24
06:12 am
exas
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO® [Yahoo! Finance]
Medium
Report
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO® [Yahoo! Finance]
5/24
06:05 am
exas
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
Medium
Report
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
5/23
05:20 pm
exas
Landmark Study from Mercy BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and Ultrasound for Ovarian Cancer Screening [Yahoo! Finance]
Medium
Report
Landmark Study from Mercy BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and Ultrasound for Ovarian Cancer Screening [Yahoo! Finance]
5/22
04:17 pm
exas
Court Dismisses Exact Sciences' ‘781 Patent Infringement Claim Against Geneoscopy [Yahoo! Finance]
Low
Report
Court Dismisses Exact Sciences' ‘781 Patent Infringement Claim Against Geneoscopy [Yahoo! Finance]
5/22
07:45 am
exas
Exact Sciences Earns 2024 Great Place To Work® Certification™ [Yahoo! Finance]
Low
Report
Exact Sciences Earns 2024 Great Place To Work® Certification™ [Yahoo! Finance]
5/22
07:30 am
exas
Exact Sciences Earns 2024 Great Place To Work® Certification™
Low
Report
Exact Sciences Earns 2024 Great Place To Work® Certification™
5/21
09:17 am
exas
Multi Cancer Early Detection Market Size, Share & Trends Analysis Report 2024-2030: Rapid Commercialization Efforts Drive Growth, Major Players Focus on Expanding MCED Test Capabilities [Yahoo! Finance]
Low
Report
Multi Cancer Early Detection Market Size, Share & Trends Analysis Report 2024-2030: Rapid Commercialization Efforts Drive Growth, Major Players Focus on Expanding MCED Test Capabilities [Yahoo! Finance]
5/21
06:10 am
exas
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy [Yahoo! Finance]
Medium
Report
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy [Yahoo! Finance]
5/21
06:05 am
exas
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
Medium
Report
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
5/15
07:49 am
exas
Foundation Fighting Blindness Partners with PreventionGenetics and InformedDNA to Advance My Retina Tracker® Genetic Testing Program [Yahoo! Finance]
Low
Report
Foundation Fighting Blindness Partners with PreventionGenetics and InformedDNA to Advance My Retina Tracker® Genetic Testing Program [Yahoo! Finance]
5/14
08:05 pm
exas
Is Climate Change Behind A Mysterious Algal Bloom In Patagonia? [Forbes]
Low
Report
Is Climate Change Behind A Mysterious Algal Bloom In Patagonia? [Forbes]
5/11
10:05 am
exas
Exact Sciences Corporation (NASDAQ:EXAS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year [Yahoo! Finance]
Medium
Report
Exact Sciences Corporation (NASDAQ:EXAS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year [Yahoo! Finance]
5/10
08:20 am
exas
Exact Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Low
Report
Exact Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
5/10
03:03 am
exas
The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients [Yahoo! Finance]
Low
Report
The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients [Yahoo! Finance]
5/9
03:40 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $90.00 to $85.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $90.00 to $85.00. They now have a "buy" rating on the stock.